Frederick Akele

Title: The Innovative Contributions of Frederick Akele

Introduction

Frederick Akele is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of immuno-oncology through his innovative patents. With a total of 2 patents, Akele's work focuses on advancing cancer treatment methodologies.

Latest Patents

Akele's latest patents include a bispecific antibody designed for ICOS and PD-L1. This multispecific antibody is structured in an mAb2 format, featuring an ICOS-binding Fab region and a PD-L1-binding Fcab region. The application of this antibody is particularly relevant in immuno-oncology, especially for the treatment of solid tumors. Additionally, he has developed combination therapies that incorporate antibodies targeting other immune checkpoint molecules such as PD-1 and CTLA-4, alongside anti-ICOS and anti-PD-L1. Another significant patent involves FC binding fragments that comprise a PD-L1 antigen-binding site. This application relates to specific binding members that target programmed death-ligand (PD-L1), which are crucial in treating cancer, infectious diseases, and inflammatory conditions.

Career Highlights

Frederick Akele has worked with prominent companies in the biotechnology sector, including F-star Therapeutics, Inc. and Kymab Limited. His experience in these organizations has allowed him to contribute to groundbreaking research and development in the field of immunotherapy.

Collaborations

Akele has collaborated with talented individuals such as Mihriban Tuna and Francisca Wollerton Van Horck. These partnerships have further enhanced his innovative capabilities and expanded the impact of his work.

Conclusion

Frederick Akele's contributions to immuno-oncology through his patents and collaborations highlight his role as a leading inventor in the field. His work continues to pave the way for advancements in cancer treatment and related therapies.